Asset Details
Do you wish to reserve the book?
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Do you wish to request the book?
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
2013
Overview
Human African trypanosomiasis, or sleeping sickness, is caused by infection with parasites of the genus Trypanosoma, transmitted by the tsetse fly. The disease has two forms, Trypanosoma brucei (T b) rhodesiense and T b gambiense; and is almost always fatal if untreated. Despite a recent reduction in the number of reported cases, patients with African trypanosomiasis continue to present major challenges to clinicians. Because treatment for CNS-stage disease can be very toxic, diagnostic staging to distinguish early-stage from late-stage disease when the CNS in invaded is crucial but remains problematic. Melarsoprol is the only available treatment for late-stage T b rhodesiense infection, but can be lethal to 5% of patients owing to post-treatment reactive encephalopathy. Eflornithine combined with nifurtimox is the first-line treatment for late-stage T b gambiense. New drugs are in the pipeline for treatment of CNS human African trypanosomiasis, giving rise to cautious optimism.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Disease
/ Genes
/ Glossina
/ Humans
/ Protozoa
/ Trypanosoma brucei gambiense - pathogenicity
/ Trypanosoma brucei rhodesiense - pathogenicity
/ Trypanosomiasis, African - diagnosis
/ Trypanosomiasis, African - drug therapy
/ Trypanosomiasis, African - epidemiology
